CAR-T Cell Therapy Companies: Complete List of Leading Developers & Pipeline 2026
CAR-T cell therapy has moved from an experimental cancer treatment into an established class of cellular immunotherapy, with multiple products now approved in the United States and a rapidly expanding pipeline of next-generation therapies.
This updated guide tracks the major CAR-T cell therapy companies, approved CAR-T products, leading clinical-stage developers, major technology platforms, and important industry changes through 2026.
2026 update: The CAR-T landscape is substantially different from the market that existed when this article was first published in 2022. FDA-approved CAR-T therapies now include products from Bristol Myers Squibb/Juno, Gilead/Kite, Novartis, Johnson & Johnson/Legend Biotech and Autolus. Meanwhile, Gilead completed its acquisition of Arcellx in 2026, bringing the investigational BCMA CAR-T therapy anito-cel fully into the Kite/Gilead organization.
What Is CAR-T Cell Therapy?
Chimeric antigen receptor T-cell therapy (CAR-T) is a form of personalized cellular immunotherapy in which a patient's T cells are collected, genetically engineered in a laboratory to recognize a cancer-associated target, expanded, and then returned to the patient.
Unlike conventional chemotherapy, CAR-T therapy is designed to harness the patient's immune system to recognize and attack malignant cells.
Most currently approved CAR-T therapies target antigens found on blood cancers, particularly CD19 or BCMA.
CAR-T therapy has demonstrated particularly important clinical activity in relapsed or refractory B-cell malignancies and multiple myeloma. However, it is not a universal cancer treatment, and eligibility depends on cancer type, disease status, prior treatment, biomarker expression, overall health and the specific regulatory indication.
FDA-Approved CAR-T Cell Therapies
The U.S. FDA currently lists several approved autologous CAR-T products. The original six major products are Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. Autolus' Aucatzyl subsequently expanded the approved CAR-T field with another CD19-directed therapy for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
The FDA also eliminated the formal REMS requirements for the six earlier autologous CAR-T products in 2025, while their product labeling continues to carry important safety information regarding cytokine release syndrome and neurologic toxicities.
Kymriah (tisagenlecleucel) was the first FDA-approved CAR-T cell therapy and remains one of the foundational products in the field.
Kymriah is a CD19-directed autologous CAR-T therapy used in specific B-cell malignancies, including certain forms of B-cell acute lymphoblastic leukemia and B-cell lymphoma.
Novartis is also developing next-generation cellular therapies and manufacturing technologies intended to make CAR-T production faster and more scalable.
Yescarta (axicabtagene ciloleucel) is a CD19-directed CAR-T therapy developed by Kite, a Gilead company.
Yescarta is an important product in the treatment of certain relapsed or refractory B-cell lymphomas and represents one of the largest commercial CAR-T franchises.
Gilead has continued to expand its cell-therapy strategy through Kite and, in 2026, completed its acquisition of Arcellx. The transaction brought the investigational BCMA-directed CAR-T therapy anito-cel fully under Gilead/Kite control.
Tecartus (brexucabtagene autoleucel) is another Kite/Gilead CD19-directed CAR-T therapy.
It is used for specific B-cell malignancies, including mantle cell lymphoma and certain adult B-cell acute lymphoblastic leukemia settings.
Breyanzi (lisocabtagene maraleucel) is a CD19-directed CAR-T therapy developed by Juno Therapeutics, now part of Bristol Myers Squibb.
Breyanzi has expanded beyond its initial lymphoma indications. In December 2025, the FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma after at least two prior lines of systemic therapy.
Abecma (idecabtagene vicleucel) is a BCMA-directed CAR-T therapy for multiple myeloma.
Its development helped establish BCMA as one of the most important targets for cellular immunotherapy in multiple myeloma.
Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T therapy developed through the collaboration between Johnson & Johnson and Legend Biotech.
Carvykti has become one of the leading CAR-T products for multiple myeloma and has received expanded FDA approvals as its clinical development program has progressed.
Aucatzyl (obecabtagene autoleucel) was approved by the FDA in November 2024 for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Aucatzyl is significant because Autolus developed its own CAR-T engineering and manufacturing platform rather than entering the market solely through one of the established large-pharma franchises.
Leading CAR-T Cell Therapy Companies in 2026
The CAR-T industry is no longer dominated only by small biotechnology companies. The commercial market now includes several major pharmaceutical companies alongside specialist cell-therapy developers.
Gilead Sciences / Kite
Gilead's Kite organization is one of the world's leading commercial CAR-T developers. Its portfolio includes Yescarta and Tecartus, while its acquisition of Arcellx adds the investigational BCMA CAR-T program anito-cel.
Bristol Myers Squibb / Juno
Bristol Myers Squibb has a major cell-therapy franchise through Juno, including Breyanzi. The company also commercializes Abecma through its partnership structure.
Novartis
Novartis is a pioneer in CAR-T therapy through Kymriah and continues to invest in next-generation manufacturing and cell-engineering approaches.
Johnson & Johnson / Legend Biotech
Johnson & Johnson and Legend Biotech have built a major multiple-myeloma cell-therapy franchise around Carvykti.
Autolus Therapeutics
Autolus is a specialist CAR-T company whose Aucatzyl became an FDA-approved therapy for relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
CAR-T Pipeline: Next-Generation Developers
The next generation of CAR-T development is focused on solving the limitations of first-generation commercial products: manufacturing time, cost, toxicity, T-cell exhaustion, antigen escape, limited persistence and poor activity against solid tumors.
Important areas of development include allogeneic CAR-T, dual-target CARs, armored CAR-T cells, logic-gated CARs, improved costimulatory domains, faster manufacturing and novel tumor targets.
Arcellx / Gilead
Arcellx became a wholly owned subsidiary of Gilead in 2026. Its lead program, anito-cel, is an investigational BCMA-directed CAR-T therapy for multiple myeloma that uses a compact D-Domain binder.
The acquisition is strategically important because it strengthens Gilead's position in BCMA CAR-T alongside its established CD19 franchise.
CARsgen Therapeutics
CARsgen is a China-based cell-therapy developer with CAR-T programs targeting hematologic malignancies and solid tumors. The company has pursued targets beyond the dominant CD19 and BCMA categories.
Caribou Biosciences
Caribou has focused on CRISPR-edited allogeneic CAR-T approaches designed to create potentially more standardized, off-the-shelf cell therapies.
Poseida Therapeutics
Poseida has developed gene-editing and cell-engineering technologies aimed at creating allogeneic CAR-T therapies. Its approach is designed to address some of the logistical limitations of individualized autologous manufacturing.
Kyverna Therapeutics
Kyverna is particularly notable because it is exploring CAR-T technology beyond traditional oncology, including autoimmune diseases. This represents one of the most important emerging directions for the platform.
Cabaletta Bio
Cabaletta Bio is another company exploring engineered T-cell therapies for autoimmune diseases, illustrating how CAR-T technology is increasingly moving beyond cancer.
Adicet Bio
Adicet has pursued allogeneic gamma-delta T-cell approaches and next-generation cellular immunotherapies, with the broader objective of creating more readily available cell therapies.
The Most Important CAR-T Targets
One of the easiest ways to understand the CAR-T competitive landscape is by looking at the antigen each company is trying to target.
- CD19: The dominant target for many approved CAR-T therapies in B-cell malignancies.
- BCMA: A major target in multiple myeloma and the basis of therapies such as Abecma and Carvykti.
- CD20: An established B-cell target under investigation in several next-generation cellular approaches.
- CD22: An important target being investigated as a strategy for overcoming CD19-negative relapse.
- GPRC5D: An emerging multiple-myeloma target that may complement or follow BCMA-directed therapy.
- CLL1: A target being explored in acute myeloid leukemia and other myeloid malignancies.
- Mesothelin: One of several targets being investigated for CAR-T treatment of solid tumors.
- Claudin 18.2: An emerging target of interest in gastrointestinal cancers.
Why Are Solid Tumors So Difficult for CAR-T?
The most dramatic clinical successes of CAR-T therapy have occurred in blood cancers. Solid tumors are considerably more difficult.
Solid tumors present several biological barriers, including heterogeneous antigen expression, physical barriers to T-cell infiltration, immunosuppressive tumor microenvironments and the risk of damaging healthy tissues that express the target antigen.
This is why the future of CAR-T is not simply about making stronger T cells. Developers are attempting to engineer cells that can find tumors, survive within hostile microenvironments, distinguish cancer from normal tissue and respond dynamically to multiple signals.
CAR-T Beyond Cancer: The Autoimmune Revolution
One of the most important developments in the cell-therapy field is the expansion of CAR-T research into autoimmune disease.
The rationale is different from cancer treatment. Instead of directing engineered T cells against malignant cells, researchers are attempting to eliminate disease-driving B cells or other pathogenic immune populations.
Early clinical research has generated interest in diseases such as systemic lupus erythematosus and other antibody-mediated autoimmune disorders.
However, these approaches remain investigational unless and until a specific product receives regulatory approval for a particular autoimmune indication.
The Major Challenges Facing CAR-T Companies
1. Manufacturing complexity
Traditional autologous CAR-T therapy requires collection of a patient's own cells, manufacturing and genetic modification, quality testing, shipping and eventual reinfusion.
This creates a highly individualized manufacturing process that can take time and requires sophisticated infrastructure.
2. Cost
CAR-T therapies are among the most expensive cancer treatments because the therapy itself is manufactured as a living cellular product rather than produced as a conventional mass-manufactured drug.
3. Cytokine release syndrome
Cytokine release syndrome (CRS) is a potentially serious inflammatory reaction that can occur after CAR-T infusion. Severity varies, and treatment may include supportive care and immune-modulating therapy such as tocilizumab.
4. Neurologic toxicity
Neurologic adverse events can also occur following CAR-T therapy. Patients require appropriate monitoring and specialized clinical management.
5. Antigen escape
Some cancers can relapse after CAR-T therapy because the malignant cells lose or alter the antigen targeted by the CAR.
This has driven development of dual-target and multi-target CAR-T therapies.
6. T-cell exhaustion
CAR-T cells can become dysfunctional or exhausted, limiting persistence and antitumor activity. Developers are therefore exploring different signaling domains, gene editing and cellular manufacturing strategies.
Where Is CAR-T Cell Therapy Heading?
The next phase of CAR-T development is likely to be defined by several major technological shifts.
- Faster manufacturing: reducing the time between cell collection and treatment.
- Allogeneic CAR-T: developing donor-derived or "off-the-shelf" cellular therapies.
- Multi-target CARs: targeting more than one cancer antigen to reduce antigen escape.
- Armored CAR-T: engineering cells to function more effectively within immunosuppressive tumor environments.
- Logic-gated CARs: using biological decision-making circuits to improve tumor selectivity.
- Solid-tumor CAR-T: overcoming antigen heterogeneity and the tumor microenvironment.
- CAR-T for autoimmune disease: using engineered cells to eliminate pathogenic immune-cell populations.
- Next-generation manufacturing: improving consistency, scalability and cost.
CAR-T Is Becoming a Platform, Not Just a Therapy
The most important change in the CAR-T industry is that the technology is evolving from a small number of personalized treatments for advanced blood cancers into a broader cellular-engineering platform.
The companies most likely to succeed will not necessarily be those with the largest number of CAR-T candidates. Competitive advantages may increasingly come from target selection, manufacturing speed, persistence, safety, cost, scalability and the ability to treat diseases that conventional CAR-T approaches cannot reach.
CAR-T Companies: How to Evaluate the Industry
Investors, researchers and patients should avoid treating every CAR-T company as equivalent. A useful evaluation framework includes:
- Clinical stage: preclinical, Phase 1, Phase 2, Phase 3 or approved.
- Target: CD19, BCMA, GPRC5D, CD22 or a novel solid-tumor antigen.
- Autologous vs allogeneic: patient-specific versus potentially off-the-shelf manufacturing.
- Indication: leukemia, lymphoma, multiple myeloma, solid tumors or autoimmune disease.
- Manufacturing: production time, scalability and consistency.
- Safety: CRS, neurologic toxicity, infections and other treatment-related risks.
- Durability: persistence of CAR-T cells and duration of clinical response.
- Regulatory status: approved, accelerated approval, investigational or preclinical.
- Financial position: particularly important for smaller biotechnology companies with expensive clinical programs.
Frequently Asked Questions
What companies make CAR-T therapy?
Major companies with approved or advanced CAR-T programs include Gilead/Kite, Bristol Myers Squibb/Juno, Novartis, Johnson & Johnson/Legend Biotech and Autolus. Numerous biotechnology companies are developing next-generation CAR-T, allogeneic CAR-T and other engineered-cell therapies.
How many CAR-T therapies are FDA approved?
The FDA has approved multiple CAR-T products for blood cancers. The major established products include Kymriah, Yescarta, Tecartus, Breyanzi, Abecma and Carvykti, with Aucatzyl adding another approved CAR-T product for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
What is the difference between CD19 CAR-T and BCMA CAR-T?
CD19 CAR-T therapies primarily target CD19, an antigen found on many B cells and B-cell cancers. BCMA CAR-T therapies target B-cell maturation antigen, which is particularly relevant to plasma cells and multiple myeloma.
Is CAR-T approved for solid tumors?
Conventional CAR-T therapy has not achieved the same regulatory success in solid tumors as it has in blood cancers. Engineered T-cell approaches are being actively studied, but the biology of solid tumors creates major challenges involving antigen selection, tumor penetration and immune suppression.
Is TECELRA a CAR-T therapy?
TECELRA is an engineered T-cell receptor therapy rather than a conventional CAR-T product. It targets the MAGE-A4 antigen in selected patients with unresectable or metastatic synovial sarcoma and is an important milestone for engineered cellular therapy in solid tumors.
Can CAR-T therapy treat autoimmune diseases?
CAR-T therapy is being investigated for autoimmune diseases, particularly conditions in which pathogenic B cells play an important role. These applications remain investigational unless a specific therapy has received regulatory approval for that disease.
What is the biggest limitation of CAR-T therapy?
Major limitations include manufacturing complexity, cost, treatment-related toxicities, antigen escape, limited persistence and difficulty targeting solid tumors. Next-generation CAR-T companies are attempting to solve these problems through improved engineering and manufacturing.
Bottom Line
CAR-T cell therapy has become one of the most important platforms in modern cancer immunotherapy.
The field has progressed from the first commercial CD19-directed therapies to a much broader ecosystem involving BCMA-targeted multiple-myeloma treatments, next-generation CAR designs, allogeneic approaches, solid-tumor research and experimental autoimmune applications.
The commercial landscape is also consolidating. Gilead's 2026 acquisition of Arcellx demonstrates the strategic value that large pharmaceutical companies continue to place on differentiated CAR-T technology and next-generation targets.
For patients, however, the most important question is not which company has the most promising pipeline. It is whether a particular cellular therapy is approved or available through an appropriate clinical trial for their specific cancer, biomarker profile and treatment history.
Sources & Regulatory References
- U.S. Food and Drug Administration — Approved Cellular and Gene Therapy Products.
- U.S. Food and Drug Administration — CAR-T product information and regulatory announcements.
- U.S. Food and Drug Administration — Breyanzi approval for relapsed or refractory marginal zone lymphoma.
- U.S. Food and Drug Administration — Aucatzyl approval information.
- U.S. Food and Drug Administration — Tecelra regulatory information.
- Gilead Sciences — Completion of the acquisition of Arcellx and anito-cel program update.
- Novartis — Kymriah CAR-T development and technology platform information.
Medical disclaimer: This article is for educational and informational purposes only. CAR-T therapy is a specialized medical treatment with potentially serious risks and is appropriate only for selected patients. Regulatory approvals and indications can change. Patients should consult a qualified hematologist/oncologist or cellular-therapy center regarding eligibility and treatment options.
.png)
Comments
Post a Comment